Celest Pharma Labs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.40 M
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
- Revenue Growth -46.43%
- Profit Growth -81.13%
- Ebitda -60.86%
- Net Worth 3.20%
- Total Assets 46.64%
About Celest Pharma Labs
Celest Pharma Labs Private Limited (CPLPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 17 March 2010 and has a history of 14 years and 11 months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹2.00 Cr.
Arun Mathad and Asha Thontadarya serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230KA2010PTC052859
- Company No.
052859
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Celest Pharma Labs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Mathad  | Managing Director | 17-Mar-2010 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Asha Thontadarya | Director | 04-Mar-2014 | Current |
Financial Performance of Celest Pharma Labs.
Celest Pharma Labs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 46.43% decrease. The company also saw a substantial fall in profitability, with a 81.13% decrease in profit. The company's net worth moved up by a moderate rise of 3.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Celest Pharma Labs?
In 2023, Celest Pharma Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Peenya Pharmaceuticals Private LimitedArun Mathad and Asha Thontadarya are mutual person
Charges (Loans)
₹20.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 2.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Nov 2022 | State Bank Of India | ₹2.00 Cr | Open |
How Many Employees Work at Celest Pharma Labs?
Unlock and access historical data on people associated with Celest Pharma Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Celest Pharma Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Celest Pharma Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
